Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cortexyme, Inc.

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Appoints June Bray to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Successfully Completes Acquisition of Novosteo
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Announces Agreement to Acquire Novosteo
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Announces Change in Executive Leadership Team
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Present New Data at AAIC 2021
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Cortexyme to Host Symposium at AAIC 2021
From Cortexyme, Inc.
Via Business Wire
Tickers CRTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.